Adalimumab and the Challenges for Biosimilars
Biologic drugs are expensive therapeutic agents and represent a large and growing segment of pharmaceutical spending. In particular, at nearly $20 billion in sales in 2018, adalimumab (Humira) dominates the worldwide biologic market, with more than twice the annual sales of the second-highest selling drug, lenalidomide (Revlimid).
